Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate - Gilead Sciences/Janssen R&D Ireland

Drug Profile

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate - Gilead Sciences/Janssen R&D Ireland

Alternative Names: Complera; Edurant/Truvada; Emtricitabine/tenofovir disoproxil fumarate/rilpivirine; Emtricitabine/tenofovir disoproxil fumarate/TMC 278; Eviplera; Rilpivirine/emtricitabine/tenofovir disoproxil fumarate; Rilpivirine/Truvada; TDF/FTC/RPV; Tenofovir disoproxil fumarate/rilpivirine/emtricitabine; Truvada/Edurant™; Truvada/TMC278

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences; Tibotec Pharmaceuticals
  • Developer Gilead Sciences; Janssen Pharmaceutical KK; Janssen R&D Ireland; Stanford University
  • Class Antiretrovirals; Deoxyribonucleosides; Nitriles; Nucleotides; Phosphonic acids; Purines; Pyrimidine nucleosides; Pyrimidines
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 31 Dec 2020 Gilead Sciences has patent protection for Emtricitabine/rilpivirine/tenofovir disoproxil fumarate in USA and European Union
  • 07 Mar 2018 Gilead Sciences completes a phase III SWEAR trial for HIV-1 infections (Treatment naive) in Italy (PO) (NCT02042001)
  • 12 Feb 2018 Emtricitabine/rilpivirine/tenofovir disoproxil fumarate is still in phase III SALIF trials in HIV-1 infections (second-line therapy) in Cameroon, Ghana, Kenya, Senegal, South Africa, Thailand and Uganda (NCT01709084)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top